Agreed its not a battle between ePAT and RAP. They both should do well in an expanding market sector. For ePAT, RAP is a good path finder to show what is possible if you get it right and its a guide to potential market cap's. Watching how RAP go about their FDA approval will also be helpful for ePAT. Hopefully, ePAT get the benefit of being a fast follower albeit with a different product but in the same market sector.
MNQ Price at posting:
0.0¢ Sentiment: None Disclosure: Held